Introduction:

The coronavirus disease 2019 (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has created a pandemic leading to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support. To date, there is no specific antivirus treatment for COVID-19. The use of convalescent plasma transfusions could be of great value in the current pandemic

Methods:

A Google Scholar and PubMed search was conducted between November 2019 and July 2020.

Results:

We found 150 articles. After using the exclusion criteria and deleting duplicate articles, we reviewed 37 studies. We included 18 studies (5 case reports, 4 case-series, 2 systematic review, 7 article reviews) with 90 participants. Recovered SARS-CoV-2 patients who may be suitable donors undergo apheresis in order to obtain convalescent plasma containing high-titer antibodies, granted they meet blood donation criteria.

Conclusion:

The benefits and effectiveness of convalescent plasma far outweigh the possible side effects, since there is no specific pharmacological therapy or vaccine available. Convalescent plasma therapy use in the management of patients at different severity levels of COVID-19 disease has become a management pillar in global management and an accessible option in developing countries.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )